David Rooklin is an American scientist, computational biologist, researcher, and biotechnology entrepreneur best known as the co-founder and CEO of Redesign Science. His professional work sits at the intersection of biology, chemistry, physics, computer science, molecular simulation, and modern artificial intelligence. Rather than becoming widely known through entertainment or social media, Rooklin built his career around computational approaches to drug discovery and the study of complex molecular interactions.
Outside scientific circles, Rooklin is also known as the husband of comedian, actor, writer, and producer Ilana Glazer. The couple married in 2017 and have generally kept their family life relatively private. While that relationship explains much of the public search interest around his name, Rooklin has an independent professional record that includes academic research at New York University, development of the AlphaSpace computational method, scientific publications, and the creation of a biotechnology company focused on computational drug discovery.
Who Is David Rooklin?
David Rooklin is a scientist and entrepreneur whose academic background combines biochemistry and computational biology. A professional biography published for a New York City life-sciences event states that he earned a BA in Biochemistry from Oberlin College and a PhD in computational biology from New York University. NYU’s Yingkai Zhang Research Group also lists Rooklin as a former graduate student who received his PhD in 2012.
His research career has centered on understanding biological molecules through computation. This field uses mathematical models, computer simulations, structural data, and algorithms to investigate questions that would be difficult to approach through laboratory experiments alone. In Rooklin’s case, an important part of that work has involved identifying opportunities for small molecules to interact with proteins, including challenging protein-protein interaction surfaces.
Rooklin later moved from academic research toward entrepreneurship. He became a co-founder of Redesign Science, a New York biotechnology company applying molecular simulation and machine-learning methods to drug discovery. NYU currently identifies him as a principal investigator associated with the company, while Redesign Science’s public company profile describes its work as combining physics-based molecular simulation with deep learning and generative AI.
David Rooklin’s Education and Scientific Background
Rooklin’s educational history helps explain the interdisciplinary direction of his career. He studied biochemistry at Oberlin College before pursuing doctoral research at New York University. His transition from biochemistry to computational biology placed him in a field where traditional biological questions can be explored using chemistry, physics, mathematics, and computing.
At NYU, Rooklin worked in the Department of Chemistry and was associated with Yingkai Zhang’s research group. The group’s alumni records list him as a PhD graduate in 2012 and indicate that he remained associated with the group during a later research period. This academic environment focused heavily on computational chemistry and molecular modeling.
After completing his doctorate, Rooklin continued scientific research. Contemporary reporting about his relationship with Ilana Glazer described him as conducting postdoctoral research in molecular modeling at NYU. His professional biography also connects his academic work to drug discovery, software development, and the computational analysis of biological systems.
This background eventually became the foundation for his move into biotechnology entrepreneurship.
What Is AlphaSpace?
One of the clearest examples of David Rooklin’s scientific work is AlphaSpace, a computational approach developed to analyze protein surfaces.
In 2015, Rooklin and collaborators Cheng Wang, Joseph Katigbak, Paramjit S. Arora, and Yingkai Zhang published a peer-reviewed paper titled AlphaSpace: Fragment-Centric Topographical Mapping To Target Protein-Protein Interaction Interfaces in the Journal of Chemical Information and Modeling. The paper is indexed by PubMed and is available through PubMed Central.
AlphaSpace was designed to help characterize protein-protein interaction interfaces. These interfaces can be difficult drug targets because they do not always contain the obvious, well-defined binding pockets traditionally associated with druggable proteins.
The approach maps regions of a protein interface and evaluates potential interaction space from a fragment-oriented perspective. In practical terms, such computational analysis can help researchers investigate where small molecular fragments might bind and which areas of a protein surface could be worth exploring during drug design.
This work is significant because identifying a biological target is only part of the drug-discovery problem. Researchers must also determine whether the target contains sites that can realistically be influenced by a drug-like molecule.
AlphaSpace provided a computational framework for examining that question.
AlphaSpace 2.0 and the Development of the Research
The AlphaSpace research did not stop with the original 2015 publication. A later paper, AlphaSpace 2.0: Representing Concave Biomolecular Surfaces using Beta-Clusters, was published in the Journal of Chemical Information and Modeling. Joseph Katigbak, Haotian Li, David Rooklin, and Yingkai Zhang were listed as authors.
AlphaSpace 2.0 expanded the underlying methodology for representing and examining concave biomolecular surfaces. The continuation of the project illustrates an important aspect of computational drug-discovery research: software and mathematical methods are typically refined as researchers encounter new molecular structures, datasets, and scientific problems.
Rooklin’s involvement in both the original AlphaSpace publication and later work provides documented evidence of his long-term interest in computational methods for understanding molecular recognition.
It also offers useful context for his later business activities. The scientific questions addressed by AlphaSpace—where molecules can bind, how protein surfaces behave, and how difficult biological targets might be approached—are closely related to broader challenges in computational drug discovery.
Founding Redesign Science
Rooklin’s move from academic science into biotechnology entrepreneurship became visible before Redesign Science’s formal launch.
In 2016, a Redesign Science team won the Technology Venture Competition at NYU Stern’s $200K Entrepreneurs Challenge. NYU Stern described the project as a biotechnology venture specializing in virtual molecular design for discovering and optimizing therapeutics aimed at pathological protein-protein interactions. The university identified David Rooklin, Ashley Modell, and Joseph Katigbak as founders of the competition team.
Public company information states that Redesign Science was founded in 2017. Rooklin has since been identified as its co-founder and CEO.
The transition is a natural extension of his academic work. Instead of using computational methods only as research tools, Redesign Science seeks to apply computational modeling and related technologies within a commercial drug-discovery organization.
That shift from academic research to biotechnology entrepreneurship is central to understanding Rooklin’s career.
What Does Redesign Science Do?
Redesign Science describes itself as a platform biotechnology company operating where physics-based molecular simulation and deep learning meet. Its stated goal is to use these technologies to support generative AI for drug discovery. The company says its therapeutic work includes protein interaction modulators aimed at targets associated with oncogenic and inflammatory diseases.
NYU’s Technology Opportunities & Ventures office similarly describes Redesign Science as using physics-based molecular simulation and deep learning. According to NYU, the company’s technology is designed to model biological systems at the molecular level, predict molecular interactions, and help create candidate compounds for further therapeutic development.
It is important to distinguish this work from the simplified idea that AI can automatically “invent a medicine.” Drug discovery remains a complex, multi-stage scientific process.
Computational systems can help researchers explore chemical possibilities, prioritize hypotheses, model molecular behavior, and select promising compounds. Those candidates still require experimental validation and, if they progress far enough, extensive preclinical and clinical testing.
Rooklin’s role therefore sits within a much larger scientific pipeline rather than replacing that pipeline.
Molecular Simulation, Physics, and AI
A defining feature of Rooklin’s professional work is the combination of physics-based molecular modeling with newer machine-learning approaches.
Molecular simulation attempts to model how atoms and molecules behave over time. Proteins are not completely rigid objects. Their structures can move, fluctuate, and adopt different conformations, and those changes may affect how another molecule interacts with them.
Physics-based simulation attempts to represent some of this molecular behavior computationally.
Artificial intelligence and machine learning can contribute in different ways. Models can be used to identify patterns in complex molecular data, generate possible chemical structures, rank possibilities, or complement simulation-based approaches.
Redesign Science publicly describes its platform as combining physics simulation with generative AI rather than relying exclusively on one technique.
For Rooklin, this combination represents a continuation of his earlier scientific interests: understanding difficult molecular targets computationally and using that information to guide drug discovery.
The NUVO Technology Platform
Public information from NYU identifies Redesign Science’s technology platform as NUVO™. According to NYU’s description, NUVO integrates physics simulation and generative AI and is used in connection with the company’s internal therapeutic pipeline.
The broad concept is to use computational models to study biological systems and molecular interactions before deciding which chemical possibilities deserve further investigation.
This can potentially make early-stage research more focused. Chemical space is enormous, and researchers cannot experimentally manufacture and test every theoretically possible molecule. Computational prioritization provides a way to narrow the search.
However, detailed technical information about proprietary biotechnology platforms is naturally limited. Public descriptions should not be interpreted as revealing every model, dataset, algorithm, training method, validation procedure, or software component used internally.
Claims about NUVO beyond what Redesign Science, NYU, scientific publications, or other reliable sources have documented should therefore be treated cautiously.
David Rooklin’s Role as a Biotechnology Entrepreneur
Rooklin’s career illustrates one route by which academic research can become a commercial biotechnology project.
Scientific discoveries at universities frequently begin with questions rather than products. Researchers develop methods, publish findings, test hypotheses, and create software or intellectual property. Some of those discoveries may eventually have commercial applications.
Rooklin’s path from AlphaSpace and molecular-modeling research into Redesign Science is an example of this transition.
The company was also recognized while still developing as a venture concept. NYU Stern reported that Redesign Science received the $75,000 Technology Venture Prize in its 2015–2016 Entrepreneurs Challenge.
A separate professional biography from a 2018 NYC Builds Bio event stated that Rooklin’s work had received NYU’s Technology Advancement and Commercialization Award and a Kairos Ventures Technology Innovation Grant.
These records provide stronger evidence of his entrepreneurial development than unsupported online estimates of his wealth, salary, or business ownership percentages.
David Rooklin and Ilana Glazer
David Rooklin’s name frequently appears in entertainment searches because he is married to Ilana Glazer, the comedian, writer, actor, producer, and co-creator of Broad City.
According to PEOPLE, Rooklin and Glazer met in 2012 in Washington Square Park in New York City. They later married in February 2017. Contemporary reports described their wedding as a private New York City Hall ceremony.
Their relationship has remained comparatively private despite Glazer’s public career.
The contrast between their professions also explains some of the interest surrounding Rooklin. Glazer works primarily in entertainment, while Rooklin’s professional life is rooted in scientific research and biotechnology.
The couple welcomed a daughter in 2021. PEOPLE reports that they have chosen not to publicly disclose their daughter’s name or show her face, reflecting the privacy they have generally maintained around their family.
Public Profile and Personal Privacy
There is considerably less verified biographical information about David Rooklin than there is about many people connected to celebrities.
That is not unusual. His primary career is in science and biotechnology rather than entertainment, and much of his public record consists of academic papers, university pages, company profiles, professional events, and occasional coverage related to Ilana Glazer.
As a result, readers should be cautious with websites that present highly specific personal information without identifying credible sources.
For example, exact estimates of Rooklin’s personal net worth are not supported by authoritative public financial disclosures found for this article. The same caution applies to detailed claims about private assets, salary, investments, property, or family matters.
A responsible biography should distinguish between information documented through academic, professional, or reputable journalistic sources and details that simply circulate across biography websites.
Scientific Publications and Research Impact
Rooklin has contributed to research concerning molecular modeling, protein surfaces, protein-protein interactions, and computational approaches relevant to drug discovery.
ResearchGate currently lists multiple publications under his profile, although database totals can change as indexing systems update their records. More importantly, primary publication databases confirm his authorship of peer-reviewed work including the original AlphaSpace paper and his co-authorship of AlphaSpace 2.0.
Scientific publication matters because it allows methods and findings to be examined by other researchers. Academic papers document assumptions, computational methods, experiments, results, and limitations in substantially greater detail than company marketing materials.
For readers trying to understand Rooklin primarily as a scientist, his peer-reviewed work is therefore a better starting point than celebrity-biography pages.
Why His Work Matters for Modern Drug Discovery
Drug discovery involves an enormous search problem. Researchers must identify biological mechanisms associated with disease, find targets that can be influenced therapeutically, design or discover suitable molecules, and repeatedly test whether those molecules behave as expected.
Computational approaches cannot remove all of that uncertainty, but they can help researchers investigate molecular systems before committing resources to experimental programs.
Rooklin’s work is especially relevant to difficult protein interaction surfaces. Traditional small-molecule drug discovery often benefits from clearly defined binding pockets. Protein-protein interfaces can present a different challenge because their surfaces may be larger, flatter, or dynamically changing.
AlphaSpace was developed specifically in the context of mapping such interfaces.
Redesign Science’s later emphasis on molecular simulation and generative AI extends this computational philosophy into a broader drug-discovery platform.
Benefits and Limitations of Computational Drug Discovery
Computational drug discovery offers several practical advantages. Researchers can examine large numbers of possibilities digitally, study structural hypotheses, prioritize molecules, and potentially reduce the amount of low-value experimental work.
Modern AI methods can add another layer by learning patterns from data and generating or ranking potential molecular designs.
But these systems have important limitations.
A computer prediction is not the same as experimental proof. Biological organisms are extraordinarily complex, and a compound that looks promising computationally may fail because of toxicity, metabolism, poor absorption, lack of efficacy, unexpected interactions, or numerous other factors.
AI models are also influenced by their training data, assumptions, objectives, and validation methods.
For that reason, the most credible interpretation of companies such as Redesign Science is not that computation eliminates laboratory drug development. Instead, computational systems are tools intended to improve decisions within that process.
What Remains Unknown About David Rooklin?
Several commonly searched details about Rooklin cannot be established confidently from strong public sources.
His private financial position, exact personal net worth, current salary, detailed ownership stake in Redesign Science, and many aspects of his family life are not publicly documented in the authoritative sources reviewed here.
Some secondary biography websites publish a specific birth date, age, birthplace, height, or net-worth estimate. Unless such details can be traced to reliable primary records or credible reporting, they should not be treated as established facts.
There is also limited public information about the internal operation of Redesign Science’s proprietary technology. This is expected for a private biotechnology company, where algorithms, experimental results, datasets, intellectual property, and development programs may contain confidential information.
Separating these unknowns from documented information produces a more accurate picture of Rooklin than filling gaps with assumptions.
Future Possibilities
Rooklin’s professional future is closely connected to a rapidly evolving area of biotechnology.
Generative AI, molecular dynamics, structural biology, computational chemistry, and large-scale computing are increasingly being combined in attempts to improve early-stage drug discovery. Redesign Science is positioned within this broader movement through its stated combination of physics-based molecular simulation and deep learning.
The long-term significance of any particular computational platform, however, depends on experimental outcomes. Ultimately, success in biotechnology is measured not only by sophisticated algorithms but by whether computational predictions translate into reproducible biological results and, eventually, useful therapies.
Rooklin’s earlier AlphaSpace research demonstrates a sustained interest in computationally examining difficult molecular interactions. How far the commercial application of these ideas progresses will depend on future scientific and clinical evidence.
Bottom Line
David Rooklin is much more than simply Ilana Glazer’s husband. His documented professional career includes a biochemistry education at Oberlin College, a PhD in computational biology from New York University, academic research in molecular modeling, development of the AlphaSpace approach, peer-reviewed scientific publications, and the co-founding of Redesign Science.
His work reflects a larger transformation taking place in biotechnology: the growing integration of computational chemistry, molecular simulation, machine learning, and generative AI into drug discovery. Redesign Science represents his effort to translate that combination from academic research into a biotechnology platform.
At the same time, Rooklin maintains a relatively limited public profile. Reliable information about his scientific education, publications, company, marriage, and professional history is available, but many personal details circulating online remain unverified. The clearest way to understand David Rooklin is therefore through the documented record: a computational scientist who moved from university research into entrepreneurship while continuing to work on technology intended to address difficult problems in molecular drug discovery.
Frequently Asked Questions
Who is David Rooklin?
David Rooklin is a computational biologist, scientist, and biotechnology entrepreneur. He is the co-founder and CEO of Redesign Science and is also known publicly as the husband of comedian and Broad City co-creator Ilana Glazer.
What does David Rooklin do for a living?
Rooklin works in biotechnology and computational drug discovery. Redesign Science describes its work as combining physics-based molecular simulation with deep learning and generative AI to support the discovery of new therapeutics.
Where did David Rooklin study?
He earned a bachelor’s degree in biochemistry from Oberlin College and a PhD in computational biology from New York University. NYU research-group records list his PhD completion in 2012.
What is AlphaSpace?
AlphaSpace is a computational approach for mapping protein-protein interaction interfaces and examining potential binding regions. Rooklin was the lead-listed author of the original 2015 AlphaSpace paper published in the Journal of Chemical Information and Modeling.
Is David Rooklin married to Ilana Glazer?
Yes. Rooklin and Ilana Glazer married in February 2017 after meeting several years earlier. They have generally kept their relationship and family life private.
Do David Rooklin and Ilana Glazer have children?
Yes. Reliable reporting states that the couple welcomed a daughter in 2021. They have deliberately kept identifying details about their child private.
What is David Rooklin’s net worth?
There is no authoritative public figure establishing David Rooklin’s personal net worth. Estimates published by unsourced biography sites should therefore be treated as speculation rather than verified financial information.
